In addition to providing the first evidence of the co‐existence of antagonistic IRE1 downstream signals in GBM and correlating those with tumor aggressiveness features, our work highlights the possibility of using IRE1‐targeted therapeutics in cancer. The gene discussed is ERN1; the disease is glioblastoma.